• STAAR Surgical Company reported past second-quarter 2026 results showing sales of US$93.54 million and net income of US$8.06 million, reversing a loss a year earlier.
• For the first half of 2026, the company more than doubled sales to US$187.06 million and moved from a large loss to profitable earnings per share, coinciding with Warren Foust’s appointment as President and Chief Executive Officer.
• Next, we’ll examine how this return to profitability, alongside Foust’s elevation to CEO, reshapes STAAR Surgical’s existing investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

STAAR Surgical Investment Narrative Recap

To own STAAR Surgical, you need to believe its implantable lens niche can keep converting procedure demand into profitable sales while it works through China uncertainty and execution risk. The sharp return to profitability in the second quarter of 2026 supports the near term earnings recovery catalyst, but the biggest risk remains how sustainable these higher volumes and margins are if distributor dynamics or refractive procedure trends soften again.

The most relevant recent development is Warren Foust’s formal appointment as President and CEO on August 4, 2026, just ahead of the strong second quarter release. His prior role overseeing research, sales, marketing, and manufacturing ties the current profitability uptick to an ongoing operational reset, which matters for investors watching whether STAAR can manage inventory better in China and support growth across the U.S., Europe, and the rest of Asia-Pacific.

Yet beneath the strong quarter, investors should still be aware that...

STAAR Surgical's narrative projects $400.0 million revenue and $36.5 million earnings by 2029. This requires 11.3% yearly revenue growth and a $57.5 million earnings increase from -$21.0 million today.

Uncover how STAAR Surgical's forecasts yield a $29.67 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Before this earnings surprise, the most pessimistic analysts saw revenue rising to only about US$375.8 million and earnings of roughly US$28 million by 2029, so this latest profit rebound may force them to revisit how much weight they give to concentrated product risk and global procedure pressures compared with more optimistic views.

Explore 3 other fair value estimates on STAAR Surgical - why the stock might be worth as much as 14% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your STAAR Surgical research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free STAAR Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate STAAR Surgical's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.